Phase II trial of pirfenidone in patients with progressive fibrosing unclassifiable ILD (uILD)

Sep 30, 2019 by [Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler K, Samara K, Gilberg F, Cottin V]

Assessment of the efficacy and safety of pirfenidone (2403 mg/day) versus placebo over 24 weeks in patients diagnosed with progressive fibrotic uILD.

Current View

Receive this presentation and more content via email